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Abstract: The prevalence of obesity has increased dramatically in recent decades, both in 
the US and worldwide. Pharmacotherapy can augment the weight-reducing effects of lifestyle 
modification and can facilitate long-term weight maintenance. However, there is a paucity of 
pharmacologic agents approved for the treatment of obesity, and the use of existing weight 
loss medications is frequently limited by contraindications, drug interactions, adverse effects, 
limited coverage by third-party payers, and cost. In recent years, there has been an increased 
understanding and appreciation of the role of gastrointestinal hormones in the control of body 
weight. One such hormone, GLP-1, also plays an important role in glucose homeostasis. GLP-1 
receptor agonists, such as exenatide and liraglutide, have been developed and are already approved 
for the treatment of type 2 diabetes. There has also been interest in the use of GLP-1 receptor 
agonists for the treatment of obesity in nondiabetic patients. This review explores the potential 
utility and limitations of exenatide and liraglutide as therapeutic agents for obesity.
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Introduction
In the US, the prevalence of obesity has increased dramatically in recent decades. 
Data from the National Health and Nutrition Examination Survey suggest that, in 
2007–2008, 34% of American adults had a body mass index (BMI) in the obese range 
($ 30 kg/m2), up from just 14% in 1971–1974.1,2 Obesity is a chronic metabolic disorder 
that affects all organ systems. Excess adiposity increases the risk of a variety of comorbid 
  conditions, including type 2 diabetes, hypertension, dyslipidemia, cardiovascular disease, 
obstructive sleep apnea, nonalcoholic fatty liver disease, osteoarthritis, and some types 
of cancer. Fortunately, even modest weight loss (eg, 5%–10% of initial body weight) 
can reduce the severity of existing comorbidities and prevent the development of new 
ones.3–5 However, weight loss also activates a complex system of neuroendocrine signals 
that increase appetite and reduce energy expenditure, making additional weight loss 
and maintenance of a lower body weight very challenging.
Pharmacotherapy for obesity
Pharmacotherapy can enhance the weight-reducing effects of lifestyle changes and 
can facilitate long-term weight maintenance.6,7 As a result, weight loss medication 
can serve as a useful adjunct to lifestyle modification in the treatment of obesity. 
However, it is important to note that obesity is a chronic condition, and weight regain 
often occurs if treatment is stopped. Therefore, in patients who choose pharmaco-
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is usually required. Unfortunately, only two medications, 
sibutramine and orlistat, are approved by the US Food and 
Drug   Administration (FDA) for long-term use.   Several 
older weight loss medications, including the appetite sup-
pressant phentermine, are approved for short-term use 
  (typically , 12 weeks), but they are frequently used off-label 
for longer periods. Unfortunately, little is known about the 
long-term safety of these older medications.
Sibutramine (Meridia®) is a centrally-acting norepineph-
rine, serotonin, and dopamine reuptake inhibitor that works 
primarily as an appetite suppressant. Orlistat (Xenical®), on 
the other hand, is a lipase inhibitor that acts in the gastro-
intestinal tract to prevent the absorption of about 30% of 
ingested fat. Dozens of randomized controlled trials confirm 
that sibutramine and orlistat are safe and modestly effective 
for long-term obesity management.8,9 Meta-analyses suggest 
that the average placebo-subtracted weight loss is 4.6% with 
sibutramine and 2.9% with orlistat.10 Clinical trials have also 
demonstrated improvements in triglycerides, high-density 
lipoprotein (HDL)-cholesterol, fasting plasma glucose, and 
hemoglobin A1c (HbA1c) with sibutramine and improvements 
in low-density lipoprotein (LDL)-cholesterol, blood pressure, 
fasting plasma glucose, and HbA1c with orlistat.8–11
Each of the currently available weight loss agents can be 
very useful in certain groups of patients, but their clinical 
utility is often limited by side effects, contraindications, or 
drug interactions. Sibutramine, for example, can produce 
small increases in blood pressure and pulse,12 and its use 
is contraindicated in patients with uncontrolled hyperten-
sion, coronary heart disease, arrhythmias, or a history of 
stroke. In addition, concomitant use of sibutramine and 
other   serotonergic agents (including many antidepressants) 
may raise the risk of the rare but potentially fatal serotonin 
syndrome. Orlistat is minimally absorbed, and systemic side 
effects are so rare that a lower-dose formulation is now avail-
able over-the-counter. However, gastrointestinal symptoms, 
such as oily stools and fecal urgency, are quite common 
and can adversely affect patient adherence.10 Furthermore, 
orlistat can interfere with the absorption of cyclosporine 
and amiodarone, and can enhance the effects of warfarin by 
reducing the absorption of vitamin K. Phentermine, which 
has sympathomimetic actions, has a side effect profile that 
is very similar to that of sibutramine, and it too is contrain-
dicated for use in patients with uncontrolled hypertension or 
cardiovascular disease.
Another barrier to the use of currently available weight 
loss medications is that their costs are often not covered by 
health insurance plans. Sibutramine and prescription-strength 
orlistat typically cost over $100 a month, which puts them 
out of reach for many patients who might benefit from their 
use. The older weight loss agents, such as phentermine, are 
typically more affordable because generic formulations are 
available.
As a result of adverse effects, contraindications, drug 
interactions, and costs, many patients who might benefit from 
pharmacotherapy for obesity do not receive this treatment. 
Additional treatment options are clearly needed. A relatively 
new class of agents, the glucagon-like peptide 1 (GLP-1) 
receptor agonist family, has garnered intense interest as a 
potential therapeutic agent for obesity management.
GLP-1 receptor agonist class
In recent years, there has been an increased understanding 
and appreciation of the role of gastrointestinal hormones in 
the control of glucose metabolism and body weight. One such 
hormone, GLP-1, is produced primarily by enteroendocrine 
L-cells located in the ileum, although these cells are also 
present throughout the small intestine and colon.13,14 GLP-1 
is secreted in response to food intake and the presence of 
nutrients in the intestinal lumen.15 GLP-1, along with other 
gut peptides, is responsible for the phenomenon known as the 
incretin effect, in which the insulinemic response to an oral 
glucose load exceeds that elicited by an equivalent amount of 
glucose delivered intravenously. GLP-1 also plays a role in 
the ileal brake mechanism, in which the presence of nutrients 
in the ileal lumen leads to a decrease in gastric motility.
The GLP-1 receptor belongs to the G-protein coupled 
family of receptors, and it is known to be present in the 
pancreas, gastrointestinal tract, brain, and other tissues, 
including the heart.16 GLP-1 receptors have also been iden-
tified in vagal afferent neurons in the rat nodose ganglion, 
and studies suggest that GLP-1 may act on target organs not 
only through classic hormonal mechanisms but also through 
neural pathways.17,18 In the pancreas, important actions 
of GLP-1 include the enhancement of glucose-dependent 
insulin synthesis and secretion, and stimulation of beta-cell 
proliferation.19 GLP-1 also inhibits inappropriate alpha-cell 
glucagon secretion, which occurs despite hyperglycemia in 
patients with type 2 diabetes.20 This reduction of glucagon 
secretion lessens hepatic glucose output and contributes to 
the antidiabetic effects of GLP-1. Important gastrointestinal 
effects of GLP-1 include reductions in gastric acid secretion 
and gastrointestinal motility, both of which are mediated 
primarily through the vagus nerve.18 In the brain, GLP-1 
receptors are found in the paraventricular nucleus and other 
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and body weight.21 GLP-1 appears to cross the blood–brain 
barrier,22,23 and postprandial increases in circulating GLP-1 
are temporally associated with neural activation in areas of 
the hypothalamus and prefrontal cortex that are involved in 
the regulation of feeding behavior.24 However, in rats, the 
GLP-1-induced increase in hypothalamic neural activity is 
attenuated by vagotomy, suggesting that the vagus nerve plays 
a role in the central nervous system response to peripheral 
GLP-1.25
GLP-1 clearly plays a role in regulating satiety, feeding 
behavior, and body weight. In rodents, intracerebroven-
tricular administration of GLP-1 reduces food intake.26,27 
In humans, peripheral administration of GLP-1 has been 
shown to increase satiety and reduce energy intake.28,29 
  Studies   suggest that chronic administration of GLP-1 can 
reduce body weight in both rats30 and humans.31 However, 
GLP-1 receptor knockout mice exhibit normal feeding 
behaviors and body weights, suggesting that GLP-1 plays 
a supporting rather than a primary role amidst the complex 
and overlapping neurohormonal pathways regulating body 
weight.32
In addition to its effects on appetite and food intake, 
GLP-1 may also play a role in energy metabolism. Studies 
in rodents suggest that administration of GLP-1 may increase 
energy expenditure and alter fuel utilization, favoring the 
oxidation of fat over carbohydrate.27,33 These findings are sup-
ported by a small (n = 46) cross-sectional study in humans, 
which suggested that higher fasting GLP-1 levels are associ-
ated with higher rates of resting energy expenditure and fat 
oxidation.34 Exogenous administration of GLP-1 was shown 
to increase resting energy expenditure in a small clinical 
trial involving 13 healthy adults.35 However, it has also been 
suggested that GLP-1 administration reduces diet-induced 
thermogenesis (ie, the energy expended as a direct result of 
food consumption, digestion, and absorption), potentially 
because of its effects on gastrointestinal motility.36,37
As compared with lean controls, obese individuals have 
been shown to have an attenuated secretion of GLP-1 in 
response to either an oral carbohydrate load38 or a mixed 
meal.39 Furthermore, Verdich et al demonstrated that diet-
induced weight loss increases postprandial GLP-1 secretion 
in obese volunteers.39 These findings, as well as the observed 
effects of GLP-1 administration on appetite, food intake, 
and body weight, as discussed above, stimulated interest 
in the use of GLP-1 in the treatment of obesity. Data about 
the antidiabetic effects of GLP-1 (ie, enhancement of beta-
cell responsiveness to elevated glucose levels, promotion 
of beta-cell proliferation, and inhibition of inappropriate 
glucagon release during hyperglycemia) also made it an 
attractive target for the treatment of diabetes. However, native 
GLP-1 is rapidly metabolized by the enzyme dipeptidyl 
peptidase-4 (DPP-4), so it has a half-life of 1–2 minutes when 
administered intravenously or around 1 hour when injected 
subcutaneously.40 As a result, the therapeutic utility of the 
peptide is limited.
Fortunately, a number of potent GLP-1 receptor agonists 
have been identified. Two such agents, exenatide and lira-
glutide, have already been approved by the FDA for the treat-
ment of diabetes, and other agents, including taspoglutide and 
albiglutide, are in various stages of development.
Exenatide
Exenatide (Byetta®) is an injectable GLP-1 receptor agonist 
that is currently approved by the FDA for the treatment of 
type 2 diabetes, either as monotherapy or as an adjunct to 
the use of oral antidiabetic agents. It is a synthetic form of 
exendin-4, a peptide hormone found in the saliva of the lizard 
Heloderma suspectum, also known as the Gila monster.41 
Exenatide and the naturally occurring exendin-4 are not full 
GLP-1 analogs, but they are potent agonists of the human 
GLP-1 receptor, exhibiting the same antidiabetic effects 
as native GLP-1. Unlike GLP-1, however, exenatide is not 
metabolized by the enzyme DPP-4, and its reported half-life 
is 2.4 hours. Exenatide undergoes renal clearance, and its half-
life is therefore prolonged in patients with kidney disease.42
effects on HbA1c and body weight  
in diabetes
Exenatide has clearly been shown to improve glycemic 
control in patients with type 2 diabetes while reducing body 
weight. In numerous randomized trials lasting up to 52 weeks, 
treatment with exenatide as monotherapy or as an adjunct to 
oral antidiabetic agents produced mean reductions in HbA1c 
of up to 1.4% and mean weight losses of up to 3.6 kg, as 
shown in Table 1.43–53 Improvements in both HbA1c and body 
weight appear to be dose-dependent.43–45
In each of the randomized trials shown in Table 1, 
exenatide-associated weight loss was progressive for the 
duration of the study, up to 52 weeks. Buse et al recently 
published interim analyses of two- to three-year data 
gathered in open-label extension trials following three 
30-week double-blind, placebo-controlled trials.53,54 In 238 
subjects treated with exenatide for at least two years, HbA1c 
decreased significantly by 1.1% and body weight decreased 
significantly by 4.7 kg, on average.54 In 217 subjects treated 
with exenatide for at least three years, HbA1c declined by Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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1.0% and body weight decreased by 5.3 kg, on average.55 
As in the original placebo-controlled Phase III trials,43–45 
significant weight loss occurred in the extension trials despite 
a lack of specific counseling regarding diet, physical activity, 
and weight management. Interestingly, there was no apparent 
weight plateau during follow-up, suggesting that exenatide-
associated weight loss is progressive for up to three years.
Other benefits
A variety of other beneficial metabolic effects have occasion-
ally but inconsistently been observed in diabetic patients 
treated with exenatide, particularly with longer-term use. 
These include improvements in systolic and diastolic blood 
pressure,50,55 LDL-cholesterol,43,55 HDL-cholesterol, and 
triglycerides.55 Off-label use of exenatide in patients with 
the metabolic syndrome (but not diabetes) has been reported; 
in clinical practice, improvements in waist circumference, 
blood pressure, total cholesterol, and triglycerides have been 
seen in these patients.56
There are little published data about the effects of 
exenatide on body weight in nondiabetic patients with 
obesity. At the 2009 Endocrine Society annual meeting, 
Trautmann et al presented preliminary data from the first 
  randomized, double-blind, placebo-controlled trial of 
exenatide for weight reduction in nondiabetic adults.57 In this 
study, 152 subjects followed a diet and exercise program 
and were randomized to receive either exenatide 10 µg 
twice daily or placebo for 24 weeks. At the end of 24 weeks, 
exenatide-treated subjects experienced a mean weight loss 
of 5.1 kg (approximately 4.7% of initial weight), which was 
significant compared with a mean loss of 1.6 kg in placebo-
treated subjects. Weight loss was progressive throughout this 
study, with no apparent weight plateau observed at 24 weeks. 
Several other clinical trials are now underway to investigate 
the effects of exenatide in nondiabetic patients, including 
patients with obesity and polycystic ovary syndrome.
Dosing and administration
The recommended dose of exenatide is 5–10 µg injected 
subcutaneously twice a day before meals. The manufacturer 
recommends starting at 5 µg twice a day for one month 
(to improve tolerability) and then increasing to 10 µg twice 
a day based on clinical response. Exenatide is currently 
available as either 5 µg or 10 µg fixed dose prefilled pens, 
with each pen containing 60 doses. A long-acting release 
(LAR) formulation of exenatide has been developed for 
weekly use and is currently in clinical trials but is not yet 
approved by the FDA.58,59 Initial research suggests that 
Table 1 Summary of randomized trials investigating the effects of twice-daily exenatide on HbA1c and body weight in patients with 
uncontrolled type 2 diabetes
Study n Study design Duration 
of study 
(weeks)
Concomitant 
diabetes 
medications
Mean change in  
HbA1c (%)
Mean change in  
body weight (kg)
Blinding Control Design 5 µg bid 10 µg bid 5 µg bid 10 µg bid
*Buse et al43 377 Triple Placebo Parallel 30 SU -0.5 -0.9 -0.9 -1.6
*Kendall et al44 733 Double Placebo Parallel 30 Met + SU -0.6 -0.8 -1.6 -1.6
*DeFronzo et al45 336 Triple Placebo Parallel 30 Met -0.4 -0.8 -1.6 -2.8
*Heine et al46 551 None insulin  
glargine
Parallel 26 Met + SU NA -1.1 NA -2.3
*Nauck et al47 501 None Biphasic 
insulin  
aspart
Parallel 52 Met + SU NA -1.0 NA -2.5
*Zinman et al48 233 Double Placebo Parallel 16 TZD ± Met NA -0.9 NA -2.1
*Barnett et al49 138 None insulin  
glargine
Crossover 16 Met or SU NA -1.4 NA -0.4 (on SU) 
-2.6 (on Met)
*Moretto et al50 232 Double Placebo Parallel 24 None -0.7 -0.9 -2.8 -3.1
§Bunck et al51 69 None insulin  
glargine
Parallel 52 Met NA -0.8 NA -3.6
*Davies et al52 235 None insulin  
glargine
Parallel 26 2 or 3 oral  
agents (Met, SU,  
or TZD)
NA -1.2 NA -2.7
*Buse et al53 464 None Liraglutide Parallel 26 Met, SU, or both NA -0.8 NA -2.9
Notes: *exenatide was administered at a dose of 5 µg bid for 4 weeks and then 5 or 10 µg bid for the duration of the study; §exenatide was 5 to 20 µg bid or tid, depending 
upon glycemic control and tolerance; 7% of volunteers received 5 µg bid, 62% received 10 µg bid, and 31% received doses above 20 µg daily.
Abbreviations: HbA1c, glycosylated hemoglobin; Met, metformin; NA, not available; SU, sulfonylurea; TZD, thiazolidinedione.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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2 mg of exenatide LAR, administered weekly, may improve 
  glycemic control more than twice-daily exenatide, with 
  comparable reductions in body weight.58,60 Other formula-
tions of exenatide that are in early phase development include 
a transdermal patch and nasal spray.
Adverse events
The most common adverse events experienced with exenatide 
treatment are gastrointestinal in nature. In the Phase III 
  trials of exenatide for type 2 diabetes, nausea was the most 
common adverse event, occurring in up to 51% of subjects 
treated with 10 µg bid.43–45 Vomiting and diarrhea occurred 
in up to 14% and 17% of exenatide-treated subjects, respec-
tively. In most patients, these gastrointestinal effects are 
mild or moderate and rarely lead to drug discontinuation. 
In the Phase III trials, less than 6% of subjects experienced 
severe nausea, and less than 4% of subjects discontinued 
treatment due to nausea. Typically, the incidence of nausea is 
greatest during the first two months of therapy and declines 
thereafter. Interestingly, nausea does not seem to contribute 
significantly to the drug’s effects on body weight, because 
patients who never experience nausea lose similar amounts 
of weight as those who do.43–45 Nausea appears to occur less 
frequently with the LAR formulation in development, and 
patient satisfaction may be greater with once-weekly rather 
than twice-daily dosing.58,61 Exenatide is not recommended 
for use in patients with gastroparesis or other disorders that 
significantly reduce gastrointestinal motility.
Since the approval of exenatide by the FDA in 2005, there 
have been postmarketing reports of pancreatitis in exenatide-
treated patients.62–64 Most cases were apparently mild or 
moderate in severity, resolving completely upon cessation 
of the drug. However, rare cases of fatal and nonfatal hemor-
rhagic or necrotizing pancreatitis have also been reported. 
Therefore, upon initiation or dose escalation, all patients 
should be informed about the potential risks and symptoms 
of pancreatitis. Furthermore, the use of exenatide should be 
avoided in patients with a history of pancreatitis or significant 
risk factors for pancreatitis, such as active alcohol abuse, 
severe hypertriglyceridemia, or symptomatic gallstones.
Coadministration of exenatide and sulfonylureas has been 
associated with an increased risk of hypoglycemia. In a Phase 
III trial, up to 36% of patients treated with both exenatide 
and a sulfonylurea experienced mild to moderate hypogly-
cemia, compared with just 3% in the placebo group, who 
continued to have poor glycemic control on a sulfonylurea 
alone.43 However, when used either as monotherapy or as an 
adjunct to metformin, exenatide does not increase the risk 
of hypoglycemia.45,50 In these circumstances,   hypoglycemia 
would not be expected to occur, because GLP-1 receptor 
agonism modulates insulin and glucagon secretion in a 
glucose-dependent manner.
Development of antiexenatide antibodies has been 
observed in up to 49% of subjects treated with exenatide for 
30 weeks.43–45 Fortunately, antibody formation does not affect 
glycemic control and does not appear to increase the risk of 
adverse events. Other common but typically mild adverse 
events observed in the Phase III trials include dizziness, 
  jitteriness, and headaches.
Contraindications
Exenatide is not recommended for use in patients with severe 
renal impairment (ie, creatinine clearance , 30 mL/min), 
including those requiring dialysis, and caution is advised 
in patients with a history of renal transplant or moderate 
renal impairment (creatinine clearance 30–50 mL/min). 
There have been postmarketing reports of increased serum 
creatinine, renal impairment, acute renal failure, and wors-
ening of chronic renal failure, sometimes requiring dialysis 
or transplantation.64,65 In some cases, affected patients were 
taking other pharmacologic agents known to affect renal 
function, such as angiotensin-converting enzyme inhibitors, 
diuretics, or nonsteroidal anti-inflammatory agents. In some 
cases, affected patients had nausea, vomiting, or decreased 
fluid intake, which may have contributed to their worsening 
renal function.
Drug interactions
Significant drug interactions are relatively rare with exenatide. 
There have been postmarketing reports of prolonged pro-
thrombin time and increased International Normalized Ratio, 
sometimes associated with bleeding, in patients on warfarin 
and exenatide.64 Since exenatide delays gastric empty-
ing, it may affect the extent and rate of absorption of oral 
medications. Therefore, medications that require a threshold 
concentration for efficacy, such as oral contraceptives and 
antibiotics, should be taken at least one hour before admin-
istration of exenatide. Exenatide has not been studied for 
use with insulin, and the manufacturer does not recommend 
concomitant use of these agents. However, off-label use of 
the combination has been reported.66–68
Patient satisfaction and adherence
Patient adherence to exenatide therapy is generally good, 
but route of administration, side effects, cost, and insurance 
coverage can impact on adherence. Some patients may Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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initially be reluctant to use injectable medications, but the 
fixed-dose prefilled pen makes administration simple and 
convenient.   Furthermore, many patients report that injections 
using fine-gauge pen needles are less painful than finger 
sticks for home blood glucose monitoring. Studies suggest 
that patients treated with twice-daily exenatide experience 
significant improvements in treatment satisfaction and reduc-
tions in diabetes-related symptoms, including fatigue and 
symptoms of hypo- and hyperglycemia.61,69 However, in 
the Phase III clinical trials of 30 weeks’ duration, 4%–10% 
of exenatide-treated subjects withdrew due to treatment-
  emergent adverse events, such as nausea.43–45 In clinical prac-
tice, discontinuation due to adverse events may be slightly 
more common.70 Cost may be another barrier to treatment, 
because the retail price of exenatide can approach $300 per 
month. Fortunately, in recent years, more third-party payers 
have included exenatide in their formularies, but some require 
prior authorization, documentation of inadequate glycemic 
control with oral agents, or higher patient co-pays. Off-label 
use (such as with concomitant insulin therapy or in patients 
without type 2 diabetes) may not be a covered benefit.
Liraglutide
Liraglutide (Victoza®) is an injectable GLP-1 receptor 
agonist currently approved by the FDA for the treatment of 
type 2 diabetes not controlled by lifestyle modification or 
oral antidiabetic therapy. Unlike exenatide, liraglutide is a 
GLP-1 analog, sharing 97% amino acid sequence homology 
with native GLP-1. Important modifications to the peptide 
  structure serve to delay its absorption from subcutaneous 
  tissue, make it resistant to DPP-4 degradation, and enable 
reversible binding to albumin.71 Over 98% of liraglutide is 
bound to albumin, and free liraglutide is metabolized by 
endogenous peptidases. Liraglutide does not undergo sig-
nificant renal or hepatic clearance. As a result, its reported 
half-life after subcutaneous administration is 13 hours.
effects on HbA1c and body weight  
in diabetes
Liraglutide has been shown to improve glycemic control in 
patients with type 2 diabetes while reducing body weight. 
In randomized trials lasting up to 52 weeks, treatment with 
1.2–1.8 mg of liraglutide daily as monotherapy or as an 
adjunct to oral antidiabetic agents produced mean reductions 
in HbA1c of up to 1.5% and mean weight losses of up to 
3.2 kg, as shown in Table 2.53,72–77 Earlier trials utilizing lower 
doses of liraglutide typically reported smaller improvements 
in HbA1c and body weight.78,79 In a head-to-head randomized 
trial sponsored by Novo Nordisk, 1.8 mg liraglutide once 
daily produced significantly greater reductions in HbA1c than 
10 µg exenatide twice daily.53
In the clinical trials shown in Table 2, weight loss occurred 
with liraglutide despite a lack of specific counseling regard-
ing diet, physical activity, and weight management. In some 
of these trials, weight loss appears to have reached a plateau 
by 12–20 weeks of treatment,73,75,77 whereas in another study, 
Table 2 Summary of randomized trials investigating the effects of once-daily liraglutide on HbA1c and body weight in patients with 
uncontrolled type 2 diabetes
Study n Study design Duration  
of study 
(weeks)
Concomitant 
diabetes 
medications
Mean change  
in HbA1c (%)
Mean change 
in body weight 
(kg)
Blinding Control Design 1.2 mg 
daily
1.8 mg  
daily
1.2 mg  
daily
1.8 mg 
daily
*vilsboll et al72 165 Double Placebo Parallel 14 None -1.4 -1.45 NA -3.0
**‡Garber et al73 746 Double Glimepiride Parallel 52 0–1 oral agents -0.8 -1.1 -2.0 -2.5
∞Nauck et al74 1091 Double Placebo or 
glimepiride
Parallel 26 Met -1.0 -1.0 -2.6 -2.8
**Zinman et al75 533 Double Placebo Parallel 26 Met + rosiglitazone -1.5 -1.5 -1.0 -2.0
∞Marre et al76 1041 Double Placebo or 
rosiglitazone
Parallel 26 Glimepiride -1.1 -1.1 +0.3 -0.2
**Buse et al53 464 None exenatide Parallel 26 Met, SU, or both NA -1.1 NA -3.2
**Russell-Jones et al77 581 Mixed§ Placebo or  
insulin glargine
Parallel 26 Met + glimepiride NA -1.3 NA -1.8
Notes: *Liraglutide doses were 0.65 mg, 1.25 mg or 1.9 mg daily (0.65 mg results not reported here); ** in these trials, liraglutide was initiated at a dose of 0.6 mg daily for 
1 week and then increased over 1–2 weeks to a dose of 1.2 or 1.8 mg daily; ‡Estimated mean change in body weight was obtained from a figure in this manuscript, as the 
mean value was not reported; ∞Liraglutide was administered at doses of 0.6, 1.2, or 1.8 mg daily. Results from the 0.6 mg arm are not shown here. Subjects in the 1.2 and 
1.8 mg dose arms underwent a dose-escalation period for 2–3 weeks after randomization; § in this trial, patients were randomly assigned to liraglutide, placebo, or open-label 
insulin glargine.
Abbreviations: HbA1c, glycosylated hemoglobin; Met, metformin; SU, sulfonylurea.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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weight loss was progressive for up to 26 weeks.53 Treatment 
with liraglutide has been shown to reduce visceral as well as 
subcutaneous adiposity in patients with type 2 diabetes.80
Other benefits
In addition to improvements in glycemic control and body 
weight, liraglutide may have other metabolic benefits in 
patients with diabetes. Significant reductions in systolic 
blood pressure73–75 and triglycerides53,72 have been observed 
with liraglutide in some studies. A recent meta-analysis of 
six Phase III clinical trials, reported at the 2009 annual meet-
ing of the Endocrine Society, suggests that liraglutide also 
lowers total and LDL-cholesterol levels and reduces the preva-
lence of the metabolic syndrome in patients with diabetes.81 
Furthermore, reductions in plasminogen activator inhibitor 1, 
an inflammatory biomarker, and B-type natriuretic peptide, 
a biomarker associated with cardiovascular risk, have been 
observed in liraglutide-treated patients with diabetes.82
Liraglutide is currently being studied as a potential 
treatment for obesity in patients without diabetes, although 
it is not yet FDA-approved for this indication. In a Phase II 
trial of 20 weeks’ duration, 564 nondiabetic obese subjects 
were randomly assigned to one of four doses of liraglutide 
(1.2, 1.8, 2.4, or 3.0 mg daily), placebo, or orlistat 120 mg 
three times daily.83 Approximately one-third of subjects had 
prediabetes at the time of randomization. During the trial, 
subjects were instructed to consume a low-fat, 500 kcal/day 
deficit diet and to increase physical activity as measured 
using pedometers. Subjects randomized to liraglutide lost 
significantly more weight than those assigned to either 
placebo or orlistat. Mean weight loss was 4.8, 5.5, 6.3, and 
7.2 kg for the 1.2, 1.8, 2.4, and 3.0 mg doses of liraglutide, 
respectively, as compared with 2.8 kg with placebo and 
4.1 kg with orlistat. In addition, the prevalence of prediabe-
tes was significantly reduced in liraglutide-treated subjects, 
as compared with those on   placebo or orlistat. Improvements 
in blood pressure were also seen with liraglutide, although 
these were not consistently greater than improvements seen 
with placebo or orlistat. In an interim analysis of data from 
an ongoing 84-week, open-label extension of this Phase II 
trial, Finer et al reported similar findings, including a reduced 
prevalence of prediabetes and some improvements in blood 
pressure with liraglutide.84
Dosing and administration
For the treatment of type 2 diabetes, the recommended dose 
of liraglutide is 1.2 to 1.8 mg injected subcutaneously once 
daily at any time of day. The manufacturer recommends 
  starting at 0.6 mg daily for one week to reduce gastrointestinal 
symptoms during initial titration. The dose should then be 
increased to 1.2 or 1.8 mg daily, based on clinical response. 
Liraglutide is currently available as a fixed-dose, prefilled 
pen delivering doses of 0.6, 1.2, or 1.8 mg.
Adverse events
As with exenatide, the most common adverse events expe-
rienced with liraglutide treatment are gastrointestinal in 
nature. In Phase III trials, nausea was the most common 
adverse event, occurring in up to 40% of subjects treated with 
liraglutide.53,72–77 Data from one head-to-head trial suggest that 
nausea is less persistent with liraglutide than with exenatide.53 
Researchers reported that the incidence of nausea is greatest 
during the first month of therapy and declines thereafter. 
Vomiting and diarrhea occurred in up to 12% and 21% of 
liraglutide-treated subjects, respectively. In most subjects, 
these gastrointestinal effects were mild or moderate, typically 
leading to drug withdrawal in less than 4% of subjects on 
1.2 mg daily or up to 11% of subjects on 1.8 mg daily.
Small but statistically significant increases in heart rate 
(eg, 2–4 beats per minute) have been observed in some of 
the Phase III clinical trials.73,76 In the head-to-head study of 
liraglutide versus exenatide, increases in heart rate occurred 
in both groups, although the change was significant only 
for liraglutide.53 Development of anti-liraglutide antibod-
ies has been observed in up to 13% of treated subjects.76,77 
Antibody formation does not appear to affect drug efficacy 
in most patients, but efficacy may be compromised in rare 
patients with extremely high antibody levels.71 Patients who 
develop anti-liraglutide antibodies may be slightly more 
likely to experience upper respiratory tract infections than 
antibody-negative patients. Other common but typically 
mild adverse events observed in the Phase III trials include 
headaches and fatigue.
Pancreatitis has been observed in the Phase III clinical 
trials of liraglutide, although it is rare.71 Therefore, lira-
glutide should be used cautiously in patients with a history 
of pancreatitis or significant risk factors for pancreatitis, 
such as active alcohol abuse, severe hypertriglyceridemia, 
or symptomatic gallstones.
Combination therapy with liraglutide and an insulin 
secretagogue may increase the risk of hypoglycemia. 
In clinical trials, up to 33% of patients treated with both 
liraglutide and a sulfonylurea experienced mild to mod-
erate hypoglycemia.53,76,77 However, when used either as 
  monotherapy or as an adjunct to metformin, liraglutide does 
not increase the risk of hypoglycemia.72,74Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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Contraindications
Treatment with liraglutide has been associated with an 
increased risk of benign and   malignant thyroid C-cell tumors 
in rodents.71 The clinical relevance of this finding is unknown, 
because there has been no reported increase in thyroid C-cell 
tumors, such as medullary thyroid carcinoma, in human 
subjects. Nevertheless, liraglutide is contraindicated for use 
in patients with a personal or family history of medullary 
thyroid carcinoma or multiple endocrine neoplasia syndrome 
type 2. Rare cases of papillary thyroid carcinoma have 
been reported in liraglutide-treated subjects. In most cases, 
these were reportedly small tumors discovered as a result of 
protocol-specified thyroid surveillance testing, which is not 
routinely recommended in clinical practice.
Since liraglutide does not undergo significant renal or 
hepatic clearance, no dose adjustment is recommended in 
patients with renal or hepatic impairment. However, there are 
limited safety data regarding the use of liraglutide in these 
patients, so it should be used cautiously.
Drug interactions
Like exenatide, liraglutide delays gastric emptying, so may 
affect the extent and rate of absorption of oral medications. 
However, no clinically significant effects have been found in 
clinical pharmacology trials conducted by the manufacturer.71 
Liraglutide has not been studied for use with insulin, and 
concomitant use of these agents is not recommended.
Patient satisfaction and adherence
As with exenatide, the route of administration, side effects, 
cost, and insurance coverage would be expected to impact 
patient adherence with liraglutide treatment. In the head-
to-head trial of once-daily liraglutide versus twice daily 
exenatide, treatment satisfaction was significantly greater 
in the liraglutide group.53 Liraglutide’s dosing schedule 
(once daily at any time of day) is certainly more conve-
nient than exenatide’s current dosing schedule (twice daily 
before meals). However, approval of an LAR formulation 
of exenatide for weekly use would likely increase patient 
satisfaction even more. Since liraglutide has only recently 
been approved by the FDA, insurance coverage is likely to 
be an issue for some patients. The retail price of liraglutide 
can approach $400 a month for the highest dose.
Other GLP-1 receptor agonists  
in development
In the future, other GLP-1 receptor agonists may also be 
available, besides exenatide and liraglutide. Taspoglutide is 
a GLP-1 analog that is currently under study by Roche for 
the treatment of type 2 diabetes.85 A sustained-release for-
mulation has been developed for weekly use. Albiglutide is 
a long-acting GLP-1 receptor agonist which is under study 
by GlaxoSmithKline for the treatment of type 2 diabetes.86 
If approved by the FDA, it would likely be administered 
once weekly.
Another intriguing strategy in the early phase of devel-
opment is the employment of peptides which act as dual 
agonists of both GLP-1 and glucagon receptors, like the 
naturally-occurring peptide, oxyntomodulin. In rodents, 
GLP-1 and glucagon receptor coagonists appear to increase 
energy expenditure, decrease food intake, reduce body 
weight, improve dyslipidemia, reduce hepatic steatosis, and 
improve glycemic control.87,88
Conclusion
GLP-1 receptor agonists have proven to be a very useful 
option in the treatment of type 2 diabetes, particularly in 
overweight and obese patients. Treatment-associated weight 
loss can be significant, which sets this class of medications 
apart from most other antidiabetic agents. In the future, 
GLP-1 receptor agonists may also play a role in the man-
agement of nondiabetic patients with obesity. Given the 
recent increase in the prevalence of obesity and the paucity 
of effective pharmacologic therapies, the development of 
new agents to treat obesity is of critical importance. GLP-1 
receptor agonists may have utility, either alone or as part of 
a multipronged approach to the pharmacologic management 
of obesity. Unfortunately, the same issues that limit the use 
of currently approved weight loss medications (ie, adverse 
effects, contraindications, limited coverage by third-party 
payers, and cost) may affect GLP-1 agonists as well.
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